The Swiss STAR trial - an evaluation of target groups for sexually transmitted infection screening in the sub-sample of men.

Schmidt, Axel Jeremias; Rasi, Manuela; Esson, Cate; Christinet, Vanessa; Ritzler, Michael; Lung, Thomas; Hauser, Christoph V.; Stöckle, Marcel; Jouinot, Florent; Lehner, Andreas; Lange, Katharina; Konrad, Torsten; Vernazza, Pietro (2020). The Swiss STAR trial - an evaluation of target groups for sexually transmitted infection screening in the sub-sample of men. Swiss medical weekly, 150, w20392. EMH Media 10.4414/smw.2020.20392

[img]
Preview
Text
smw_2020_20392__1_.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (626kB) | Preview

OBJECTIVES

In Switzerland, universal health insurance does not cover any routine testing for sexually transmitted infections (STIs), not even in individuals at high risk, and extra-genital swabbing is not standard of care. We determined the prevalence and incidence of human immunodeficiency virus (HIV), viral hepatitis and non-viral STIs in a multicentre prospective observational cohort of multi-partner men who have sex with men (MSM) and other men.

MATERIALS AND METHODS

Between January 2016 and June 2017, we offered free STI testing to all men with multiple  sexual partners (three or more in the previous 12 months), with follow-up examinations every 6 months. We used multiplex polymerase chain-reaction testing (for Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis, Mycoplasma genitalium) on pooled swabs (pharynx, urethra/vagina, anus), and antibody tests for HIV and Treponema pallidum at every visit, and for hepatitis B/C at baseline.

RESULTS

We screened 779 multi-partner MSM and 92 other men. Previously undiagnosed HIV was found in 0.5% vs 0.0%, respectively and T. pallidum antibodies in 15.3% vs 1.1%. STIs requiring antibiotic treatment comprised: active syphilis 1.7% vs 0.0%; N. gonorrhoeae 10.3% vs 0.0%; C. trachomatis 8.7% vs 1.1%. One in four MSM versus 1 in 100 other multi-partner men had any of these three STIs at baseline. 10.4% vs 1.3% had a history of hepatitis B, 31.9% vs 47.3% had no immunity (HBs-AB <10 IU/l). Ten MSM had HCV antibodies (1.4%), with 8 out of the 10 being MSM with HIV; HCV seroprevalence was 0.3% among HIV-negative MSM. In MSM, incidence of the three bacterial STIs was 25.5 per year over 333 person years of follow-up, HIV incidence was 0.3%. Non-condom-use (in the last 3 months) for anal/vaginal sex was not associated with STIs. Independent risk factors were sex with men (adjusted odds ratio [aOR] 16.4) and the number of sexual partners (aOR 2.3 for >20).

CONCLUSION

Among MSM, but not among other multi-partner men, STIs, mostly asymptomatic, are common. Given the high risk of onward transmission, low-cost or free routine screening of multi-partner MSM is a public health priority.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

UniBE Contributor:

Hauser, Christoph Victor

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1424-3997

Publisher:

EMH Media

Language:

English

Submitter:

Annelies Luginbühl

Date Deposited:

15 Jan 2021 11:27

Last Modified:

17 Jan 2021 02:55

Publisher DOI:

10.4414/smw.2020.20392

PubMed ID:

33382077

BORIS DOI:

10.48350/150560

URI:

https://boris.unibe.ch/id/eprint/150560

Actions (login required)

Edit item Edit item
Provide Feedback